Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 5/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | FCER2 | P06734 | 2/20 | 0.53 |
| ▸ | MMP1 | P03956 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | MMP3 | P08254 | 1/20 | 0.51 |
| ▸ | MME | P08473 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16182414 | 0.89 | POLB (0.57) | HPGDSPOLBSMN1; SMN2FCER2MMP1 | |
| SCHEMBL1012023 | 0.89 | MME (0.63) | POLBSMN1; SMN2MME | |
| SCHEMBL19584939 | 0.89 | MMP9 (0.56) | HPGDSFCER2MMP1EPHX1CAPN1 | |
| SCHEMBL9109075 | 0.89 | HPGDS (0.56) | HPGDSFCER2MMP1EPHX1CAPN1 | |
| SCHEMBL1012022 | 0.89 | MME (0.63) | POLBSMN1; SMN2MME | |
| SCHEMBL1012053 | 0.89 | MME (0.63) | POLBSMN1; SMN2MME | |
| Ammonia Solution, Strong SCHEMBL10824805 | 0.87 | MME (0.61) | POLBSMN1; SMN2MME | |
| Hydrochloric Acid SCHEMBL1262435 | 0.87 | MME (0.61) | POLBSMN1; SMN2MME | |
| Ammonia Solution, Strong SCHEMBL10824808 | 0.87 | MME (0.61) | POLBSMN1; SMN2MME | |
| SCHEMBL15743886 | 0.86 | HPGDS (0.53) | HPGDSFCER2MMP1EPHX1CAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6777564-B2 | AS ANTITUMOR AGENTS | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2004-08-17 | — | — | US | disclosed |
| US-20030149092-A1 | Anthraquinone compound | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2003-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149092-A1 | Anthraquinone compound | ANTXR2, AAAS, H1-0 | HPGDS 2074/4885POLB 2961/4885SMN1; SMN2 4310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.